Search results for " stroma"

showing 10 items of 172 documents

Isolation and Characterization of CD276+/HLA-E+ Human Subendocardial Mesenchymal Stem Cells from Chronic Heart Failure Patients: Analysis of Differen…

2012

Mesenchymal stem cells (MSCs) are virtually present in all postnatal organs as well as in perinatal tissues. MSCs can be differentiated toward several mature cytotypes and interestingly hold potentially relevant immunomodulatory features. Myocardial infarction results in severe tissue damage, cardiomyocyte loss, and eventually heart failure. Cellular cardiomyoplasty represents a promising approach for myocardial repair. Clinical trials using MSCs are underway for a number of heart diseases, even if their outcomes are hampered by low long-term improvements and the possible presence of complications related to cellular therapy administration. Therefore, elucidating the presence and role of MS…

Pathologymedicine.medical_specialtyB7 AntigensHeart VentriclesGene ExpressionCell SeparationBiologyCell therapyHLA-EAntigens CDOsteogenesisCellular cardiomyoplastymedicineHumansImmunologic FactorsMyocardial infarctionCells CulturedHeart FailureAdipogenesisMesenchymal stem cells human heart stromal progenitors post-infarct chronic heart failure cardiomyocyte markers immune modulation inflammation cardiac remodelling regenerative medicineSettore BIO/16 - Anatomia UmanaHistocompatibility Antigens Class IMesenchymal stem cellMesenchymal Stem CellsCell BiologyHematologyAnatomymedicine.diseaseClinical trialmedicine.anatomical_structureVentricleHeart failureChondrogenesisBiomarkersDevelopmental BiologyStem Cells and Development
researchProduct

Central Odontogenic Fibroma combined with Central Giant Cell lesion of the mandible. Immunohistochemical profile.

2011

Central Odontogenic Fibroma is a benign neoplasm of mesenchymal origin that makes up less than 5% of odontogenic tumors. There is a variation of this lesion that includes a zone of giant cells. This neoplasm is characterized by fibroblast proliferation, a component of apparently inactive odontogenic epithelium within a mature connective tissue stroma and multinucleated osteoclast-like giant cells. Clinically, it manifests as a slow-growing central lesion, which causes painless cortical expansion and may occasionally cause the displacement of adjacent dental organs or resorption. We present a new case of this combined lesion that was revealed radiographically as a well-defined radiolucent ar…

Pathologymedicine.medical_specialtyCD68Mesenchymal stem cellMandibleConnective tissue stromaOdontologíaAnatomyBiology:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludEpitheliumLesionmedicine.anatomical_structureGiant cellUNESCO::CIENCIAS MÉDICASCentral odontogenic fibromamedicinemedicine.symptomGeneral DentistryJournal of Clinical and Experimental Dentistry
researchProduct

Squamous odontogenic tumor-like proliferation in a radicular cyst: a case report

2013

The squamous odontogenic tumour is a rare benign neoplasm whose aetiology remains unknown. It usually appears in the jaw and its origin could be related to the ephitelial remnants of Malassez. Histologically comprises numerous islets of squamous, non-keratinized, well-differentiated and rounded epithelial cells a fibrous stroma without signs of atypical cells. There is a non-neoplastic lesion with the same histological pattern than the squamous odontogenic tumour. This entity is characterized by squamous odontogenic tumour proliferations isolated into the cyst wall of an odontogenic cyst. It is rare and has a benign behavior. It has been suggested that these epithelial proliferations could …

Pathologymedicine.medical_specialtyCase ReportOdontologíaMalignancyOdontologiaQuistosLesionFibrous stromaSquamous odontogenic tumorOdontogenic cystmedicineNeoplasmGeneral DentistryTumorsRadicular CystOral Medicine and PathologySquamous odontogenic tumourbusiness.industry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludstomatognathic diseasesCysts (Pathology)DentistryUNESCO::CIENCIAS MÉDICASmedicine.symptombusiness
researchProduct

Immunoreactivity using anti-ERG monoclonal antibodies in sarcomas is influenced by clone selection.

2014

The aim of the present study was to explore ERG immunoreactivity in a series of sarcomas, GIST and malignant rhabdoid tumor (MRT), considering the not fully elucidated specificity and sensitivity of this antibody. Paraffin-embedded tissue microarrays from those tumors were stained with anti-ERG against the C-terminus [(EPR3864(2)] and N-terminus (Clone 9FY). EPR3864(2) was positive in almost all angiosarcomas, and MRT.GIST were positive in a large proportion of cases (38.4%), and more than half the synovial sarcomas (52.7%) revealed EPR3864(2) staining. Several chondrosarcomas, osteosarcomas, rhabdomyosarcoma and Ewing's sarcoma family of tumors (ESFT) presented EPR3864(2) expression in a l…

Pathologymedicine.medical_specialtyGastrointestinal Stromal TumorsClone (cell biology)BiologySensitivity and SpecificityPathology and Forensic MedicineFusion geneTranscriptional Regulator ERGmedicineHumansRhabdomyosarcomaRhabdoid TumorRetrospective StudiesTissue microarrayBrain NeoplasmsSarcomasEwing's sarcomaAntibodies MonoclonalEwing's sarcomaSarcomaCell Biologymedicine.diseaseImmunohistochemistrySynovial sarcomaKidney NeoplasmsERGTrans-ActivatorsImmunohistochemistrySarcomaPathology, research and practice
researchProduct

Gastrointestinal stromal tumors (GISTs): Focus on histopathological diagnosis and biomolecular features

2007

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract that are believed to originate from a neoplastic transformation of the intestinal pacemaker cells (interstitial cells of Cajal) normally found in the bowel wall or their precursors. Although the microscopic features have been known for a long time, the defining characteristic of GIST is the presence of the cell-surface antigen CD117 (KIT), which is demonstrated by immunohistochemistry. KIT, which is a growth factor transmembrane receptor, is the product of the proto-oncogene c-kit (chromosome 4). Surgical removal remains the only curative treatment for patients with GISTs. Tumor size, mitotic index,…

Pathologymedicine.medical_specialtyGastrointestinal Stromal TumorsPDGFRAProto-Oncogene MasHumansMedicineGastrointestinal stromal tumors; Histopathological diagnosis; Molecular biology; Novel therapies; Drug Resistance Neoplasm; Gastrointestinal Stromal Tumors; Humans; Hematology; OncologyNeoplastic transformationGastrointestinal stromal tumors (GISTs)neoplasmsbiologyGiSTbusiness.industryCD117SunitinibImatinibHematologymedicine.diseasedigestive system diseasesImatinib mesylateOncologyDrug Resistance Neoplasmbiology.proteinCancer researchbusinessmedicine.drug
researchProduct

The bone marrow stroma in hematological neoplasms—a guilty bystander

2011

In the setting of hematological neoplasms, changes in the bone marrow (BM) stroma might arise from pressure exerted by the neoplastic clone in shaping a supportive microenvironment, or from chronic perturbation of the BM homeostasis. Under such conditions, alterations in the composition of the BM stroma can be profound, and could emerge as relevant prognostic factors. In this Review, we delineate the multifaceted contribution of the BM stroma to the pathobiology of several hematological neoplasms, and discuss the impact of stromal modifications on the natural course of these diseases. Specifically, we highlight the involvement of BM stromal components in lymphoid and myeloid malignancies, a…

Pathologymedicine.medical_specialtyMyeloidStromal cellbusiness.industrymedicine.diseaseArticleLymphomaBone marrow stroma hematological neoplasmsmedicine.anatomical_structureOncologyStromaBone MarrowHematologic NeoplasmsmedicineBystander effectAnimalsHumansHematological neoplasmBone marrowStromal CellsbusinessHomeostasisNature Reviews Clinical Oncology
researchProduct

Endometrial stromal sarcomas: immunohistochemical, electron microscopical and cytogenetic findings in two cases.

1999

Uterine sarcomas are approximately 3% of all malignant uterine corpus tumours. Of these, the tumours that originate solely in the stromal elements of the uterine wall are infrequent and have not been well characterized cytogenetically. We report two cases of endometrial stromal sarcomas (ESS), one low grade and one high grade, diagnosed by conventional histology, immunocytochemistry, electron microscopy and cytogenetics. Morphologically clear-cut differential structures were seen at optical, immunohistochemical, and electron microscopic levels, permitting a clear differential diagnosis. The low-grade ESS expressed hormonal receptors and vimentin, whereas the high-grade ESS showed no hormone…

Pathologymedicine.medical_specialtyStromal cellSarcoma Endometrial StromalChromosomes Human Pair 20VimentinChromosome DisordersPathology and Forensic MedicineImmunoenzyme TechniquesFatal OutcomeComplex KaryotypemedicineBiomarkers TumorHumansMolecular BiologyAgedChromosome AberrationsbiologyCytogeneticsKaryotypeHistologyCell BiologyGeneral MedicineGene rearrangementMiddle Agedmedicine.diseaseCombined Modality TherapyChromosome BandingEndometrial NeoplasmsMicroscopy ElectronKaryotypingbiology.proteinChromosomes Human Pair 6FemaleSarcomaVirchows Archiv : an international journal of pathology
researchProduct

Tumor del estroma gastrointestinal y schwannoma gástricos: una presentación inusual en un paciente sin neurofibromatosis

2020

The majority of gastric neoplasms are of epithelial type. Stromal tumours are the next most frequent and are most commonly gastrointestinal stromal tumours, followed by leiomyoma and schwannoma. We present an exceptional case of a patient with a gastrointestinal stromal tumour with suspicion of residual gastric disease, which was diagnosed post-operatively as a schwannoma.

Pathologymedicine.medical_specialtyStromal cellbusiness.industryStromal tumoursSchwannomaGastrointestinal stromal tumoursmedicine.diseasePathology and Forensic Medicine03 medical and health sciences0302 clinical medicineLeiomyoma030220 oncology & carcinogenesisotorhinolaryngologic diseasesMedicine030211 gastroenterology & hepatologybusinessneoplasmsGastric NeoplasmRevista Española de Patología
researchProduct

Cell therapy of periodontium: from animal to human?

2013

Periodontitis is a chronic inflammatory disease affecting the soft and hard tissues supporting the teeth, which often leads to tooth loss. Its significant impact on the patient's general health and quality of life point to a need for more effective management of this condition. Existing treatments include scaling/root planning and surgical approaches but their overall effects are relatively modest and restricted in application. The goal of regenerative therapy of periodontal defects is to enhance endogenous progenitors and thus promote optimal wound healing. Considering that the host or tissue might be defective in the periodontitis context, it has been proposed that grafting exogenous stem…

Periodontitislcsh:QP1-981clinical trials as topicbusiness.industryPhysiologyRegeneration (biology)DentistryContext (language use)Periodontiummedicine.diseaseBioinformaticsRegenerative medicinelcsh:PhysiologyCell therapyMini Review Articlebone regenerationPhysiology (medical)tissue engineeringmedicineStem cellbusinessBone regenerationmesenchymal stromal cellsperiodontitisFrontiers in Physiology
researchProduct

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study

2021

Background Despite its proven activity as third-line treatment in gastrointestinal stromal tumors (GIST), regorafenib can present a poor tolerability profile which often leads to treatment modifications and transient or permanent discontinuation; thus, in clinical practice physicians usually adopt various dosing and interval schedules to counteract regorafenib-related adverse events and avoid treatment interruption. The aim of this real-world study was to investigate the efficacy and safety of personalized schedules of regorafenib in patients with metastatic GIST, in comparison with the standard schedule (160 mg daily, 3-weeks-on, 1-week-off). Patients and methods Institutional registries a…

Phenylurea CompoundOncologyCancer Researchmedicine.medical_specialtyScheduleStromal cellPyridinesGastrointestinal Stromal TumorsPyridinePersonalized treatmentchemical and pharmacologic phenomenaMultikinase inhibitorchemistry.chemical_compoundQuality of lifeRetrospective Studieimmune system diseaseshemic and lymphatic diseasesInternal medicineRegorafenibmedicineHumansOriginal ResearchRetrospective StudiesGiSTbusiness.industryPhenylurea Compoundstoxicityhemic and immune systemspersonalized treatmentdigestive system diseasesquality of lifeOncologychemistryregorafenibGIST; personalized treatment; quality of life; regorafenib; toxicity; Humans; Phenylurea Compounds; Pyridines; Retrospective Studies; Gastrointestinal Stromal TumorsbusinessHumanGISTESMO Open
researchProduct